HAE - Haemonetics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

HAE is currently covered by 5 analysts with an average price target of $71.02. This is a potential upside of $16.72 (30.79%) from yesterday's end of day stock price of $54.3.

Haemonetics's activity chart (see below) currently has 157 price targets and 140 ratings on display. The stock rating distribution of HAE is 20.69% HOLD and 79.31% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 68.09% with an average time for these price targets to be met of 300.73 days.

Highest price target for HAE is $100, Lowest price target is $68, average price target is $86.2.

Most recent stock forecast was given by ANDREW COOPER from RAYMOND JAMES on 11-Aug-2025. First documented stock forecast 31-May-2013.

Currently out of the existing stock ratings of HAE, 6 are a HOLD (20.69%), 23 are a BUY (79.31%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$78

$24.26 (45.14%)

$105

8 days ago
(11-Aug-2025)

6/11 (54.55%)

$25.53 (48.66%)

163

Buy

$68

$14.26 (26.54%)

$84

12 days ago
(07-Aug-2025)

3/12 (25%)

$12.37 (22.24%)

358

Buy

$95

$41.26 (76.78%)

$95

1 months 8 days ago
(11-Jul-2025)

19/32 (59.38%)

$19.48 (25.79%)

303

Hold

$90

$36.26 (67.47%)

$85

1 months 10 days ago
(09-Jul-2025)

11/12 (91.67%)

$12.48 (16.10%)

168

Buy

$100

$46.26 (86.08%)

$100

2 months 30 days ago
(20-May-2025)

5/15 (33.33%)

$31.09 (45.12%)

215

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is HAE (Haemonetics) average time for price targets to be met?

On average it took 300.73 days on average for the stock forecasts to be realized with a an average price target met ratio 68.09

Which analyst has the current highest performing score on HAE (Haemonetics) with a proven track record?

MIKE MATSON

Which analyst has the most public recommendations on HAE (Haemonetics)?

Mike Matson works at NEEDHAM and has 36 price targets and 37 ratings on HAE

Which analyst is the currently most bullish on HAE (Haemonetics)?

Lawrence Keusch with highest potential upside - $101.26

Which analyst is the currently most reserved on HAE (Haemonetics)?

David Roman with lowest potential downside - -$60.05

Haemonetics in the News

Haemonetics (NYSE:HAE) Surprises With Strong Q2 But Stock Drops 24%

Blood products company Haemonetics (NYSE:HAE). reported Q2 CY2025 results topping the market’s revenue expectations , but sales fell by 4.4% year on year to $321.4 million. Its non-GAAP profit of $1.10 per share was 8.3% above analysts’ consensus estimates. Is now the time to buy Haemonetics? Find out in our full research report. Haemonetics (HAE)...

Haemonetics stock price target lowered to $68 at Needham on competition

Investing.com – Needham has lowered its price target on Haemonetics (NYSE:HAE) to $68.00 from $84.00 while maintaining a Buy rating on the stock. The company’s shares currently trade at $57.98, near their 52-week low of $55.30. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The price target reduction follows...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?